Drug intelligence / Profile preview

WD-2010

Development stage: Unknown
Lead developer: Shanghai WD Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

WD-2010 is a small molecule pharmaceutical candidate currently in Phase 1 clinical development for the treatment of Parkinson's disease, specifically targeting the management of "OFF" episodes. Developed by WD Pharmaceutical (also known as Nanjing Wende Pharmaceutical), the drug is part of a specialized pipeline focused on central nervous system (CNS) disorders and motor fluctuations. "OFF" episodes occur when the therapeutic effects of standard levodopa therapy diminish, leading to a return of Parkinsonian motor symptoms; WD-2010 aims to address this unmet need by potentially providing more stable symptom control or rapid rescue from these episodes.

Targets

DDC (Aromatic L-amino acid decarboxylase)

Beyond the preview

Go deeper on WD-2010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WD-2010.

Explore the full profile